

Immunology in Pulmonology



Figure 2 Transfusion of a patient with animal blood (from Scultatus, courtesy of the National Library of Medicine)

Dr Liew Woei Kang

MBBS, MRCPCH, FAMS, FAAAAI

Consultant Paediatrician

Paediatric Immunology and Allergy

SBCC Baby & Child Clinic, Gleneagles Medical Centre

Visiting Consultant, Paediatric Department
KK Women's and Children's Hospital, Singapore

President, College of Paediatrics and Child Health
Academy of Medicine Singapore

Outline

- Primary Immunodeficiency Diseases/
Inborn errors of Immunity
 - Respiratory manifestations
 - Red flags
 - Workup
- Asthma
 - Immunology
 - Therapies

Primary immunodeficiency

→ Inborn Errors of Immunity

"When you hear hoof beats,
think of horses not zebras"

~Dr. Thomas Woodward
Professor, University of Maryland
School of Medicine

According to John Sotos' book Zebra Cards: An Aid to
Obscure Diagnoses, the term was first coined in
the 1940s.

What does the phrase mean? While in training,
doctors are taught to look for the most
common causes of illness – the horses.
Those with primary immune deficiencies and
other rare diseases are the zebras.


www.immunecompetence.org

We say embrace being a Zebra!






- Primary immunodeficiency diseases is a window to the immune system
- Inborn Errors of Immunity
- ~350 single gene defect described



PID - Immune system failure



Respiratory manifestations of PID

■ Infections

– Bacteria

- Pneumonia/Emphyema/
Bronchiectasis
- Lung abscess

– Viral

- Pneumonitis/ ARDS

– Fungal/PCP

– Mycobacterium

■ Allergy

– Asthma, ABPA

■ Interstitial lung disease

– Granulomatous inflammation

■ Malignancy

– Mediastinum Lymphoma

PIDs

Agammaglobulinaemia/CVID/CID

Hypogamm/Complement deficiency

CGD, AD-HIES

SCID/ CID

SCID/ CID/ XHIGM

SCID/CGD/MSMD

IgAD, CVID, CID

CVID/CGD

CID (NBS), WAS, Artemesis

“Reg Flags” for Primary Immunodeficiency

Adapted from Jeffery Modell Foundation poster: 10 Warning signs of PID

| | | |
|---|--|---|
| 1 | Family history | Positive for early unexplained death, sepsis, recurrent infections, or specific immunodeficiency diagnoses |
| 2 | Frequent infections | Elevated frequency of documented infections including: <ul style="list-style-type: none">• Pneumonia ≥ 2 per year• Sinus infection ≥ 2 per year• Ear infections ≥ 4 per year |
| 3 | Chronic/ Unusual sites/ Complications of infection | Bronchiectasis Recurrent deep skin or organ abscesses (e.g., liver or brain abscess) Two or more deep seated infections ARDS from common respiratory infections |
| 4 | Infecting organism | Opportunistic, recurrent, or unusual pathogens (e.g. <i>Pneumocystis Carinii</i> , <i>Mycobacterium bovis</i> , <i>Aspergillus</i> , <i>Serratia</i> , <i>Nocardia</i> , <i>Burkholderia cepacia</i>) Persistent thrush in mouth or elsewhere on skin after 1 year old |
| 5 | Response to therapy | Poor response or recurring infection after antimicrobial discontinuation; Need for IV antibiotics to clear infections |
| 6 | Other signs | Failure to thrive, dermatitis, recurrent diarrhoea, history of autoimmune disease, malignancy |

Pattern of illness associated with PID

| Disorder | Illness | |
|------------------------|--|---|
| | Infection | Others |
| Antibody | Sinopulmonary infection (pyogenic, encapsulated bacteria) Gastrointestinal (enteroviruses, <i>Giardia lamblia</i>) | Autoimmune disease (autoantibodies, inflammatory bowel disease) |
| Cell-mediated immunity | Pneumonia (pyogenic bacteria, <i>Pneumocystis carinii</i> , viruses) Gastrointestinal (viruses) Skin, mucus membrane (fungi - <i>Candida</i>) | Graft vs host disease in SCID |
| Complement | Sepsis and other blood-borne encapsulated bacteria (<i>Streptococcus, Pneumococcus, Neisseria</i>) | Autoimmune disease (SLE, GN) |
| Phagocytes | Skin, reticulendothelial system, abscesses (Catalase positive organism: <i>Staph aureus, Burkholderia cepacia, Aspergillus sp, Nocardia sp, and Serratia marcescens.</i> | |

Host Defense Mechanisms

- breakdown results in recurrent infections

■ INNATE IMMUNITY


- Skin and Mucosal Barriers
- Pattern recognition molecules/Toll-Like Receptors/ Dendritic cells/ HLA – self vs microbial recognition
- Interferons/ Cytokines
- **Complement**
- Macrophages/ NK cells/ **Phagocytes**

■ ADAPTIVE IMMUNITY


- **B cells – humoral (antibody) arm**
- **T cells – cellular arm**

Classical PID


Innate and Adaptive Immunity



Innate and Adaptive Immunity







Barriers of the Lungs




- Lung anatomical defects predispose to recurrent infections
 - CCAM, TOF
 - PCD, Cystic fibrosis


Acute bacteria infections are mainly cleared by the innate immune system



Cytokines, anaphylotoxins and arachidonic acid metabolites attract neutrophils to the site of infection. These form pus.




Meanwhile, antigen and dendritic cells reach a local lymph node and stimulate a Th2 response.




Newly produced antibody clears the infection by activating more complement and opsonizing bacteria.

Response to encapsulated bacteria




Encapsulated bacteria have large sugar capsules, which do not stimulate T cells or induce conventional antibodies.




T-independent B cells overcome the need for T cell help by recognizing multiple, repeating sugar motifs.

Fig. 3.20.3 T-independent B cells are activated by sugar antigens on bacterial capsules.

Age-related changes in the serum concentration of immunoglobulins




Defects in B-cell development can lead to humoral immune deficiency



PIDs with Bacteria infections

- IgA Deficiency (IgAD)
- X-linked agammaglobulinemia (XLA)
- Common Variable Immunodeficiency (CVID)
- AD Hyper-IgE syndromes (AD HIES)
- Chronic granulomatous disease (CGD)
- X-linked hyper-IgM syndrome (XHIGM)

IgA Deficiency




- Most common ID, 1:700 Caucasians
- Uncommon in Asians, 1:2600-5300 China, 1:15000-18500 Japan
- Autosomal recessive / dominant
- Males = Females
- B cell maturation defect in IgA production
- $\text{IgA} < 0.07\text{g/L}$ with normal IgM and IgG, $> 4\text{yrs}$ old
- Small proportion with IgG subclass (IgG2) defect
- Normal IgG response to most vaccines, variable response to polysaccharide vaccines (depending on IgG2 levels)
- May progress into CVID

IgA Deficiency

■ Presentation:

- 85-90% asymptomatic
- Recurrent sinopulmonary infections (esp. those with IgG2 subclass def)
- Gastrointestinal infections/ Disorders
- Autoimmunity
- Allergic disorders
- Malignancy



Clinical associations of referred IgA-deficient subjects^a


| Condition | Number of patients | Patients (%) | Median age | IQR ^b years |
|----------------------------|--------------------|--------------|------------|------------------------|
| Recurrent Infections | 63 | 50 | 12.5 | 26.0 |
| Autoimmunity | 34 | 28 | 29.0 | 27.5 |
| Allergy/Asthma | 16 | 13 | 10.5 | 36.5 |
| Cancer | 9 | 7 | 59.0 | 15.0 |
| Healthy | 7 | 6 | 25.0 | 22.5 |
| Gastrointestinal disorders | 4 | 3 | 24.5 | 24.0 |

N = 127.

^a Twenty-nine patients (23%) had more than one of these conditions.

^b Interquartile range (age).

IgA Deficiency



■ Allergic disorders


- Atopy in IgA deficiency range from 13-84%
- Dermatitis resembling AD present
- Increased incidence of asthma, AR/AC and food allergies
- Total IgE raised or normal
- Secretory IgA protective of allergy development?

■ Treatment

- Nil for asymptomatic group
- Clinical importance of screening for anti-IgA antibodies as at risk of blood transfusion anaphylactic reaction
- Range from prophylactic antibiotics to IVIG in those with IgG subclass deficiency

X-linked (Bruton's) Agammaglobulinaemia

- Males, Xq21.3-22, familial
- Recurrent pyogenic infections
- All Ig classes < 2SD's for age
- < 2% CD19+ B cells
- Absent isohemagglutinins, poor response to vaccines
- No palp. lymph nodes, no germinal centers
- Cell mediated immunity intact
- BM - normal B cell precursors (pre-B)
- Mutations in Btk tyrosine kinase, 1:200,000
- Lifelong IVIG replacement
 - reduced lifespan Cx by bronchiectasis and sclerosing cholangitis
- AD-like eruptions occur (but IgE low), superimposed with infections



X-linked (Bruton's) Agammaglobulinaemia

- Recurrent pyogenic infections in skin and sinopulmonary tract
 - Encapsulated bacteria eg. *Streptococcus Pneumoniae*, *Haemophilus influenzae*, *Pseudomonas aeruginosa*
- Prone to bronchiectasis
- Severe enterovirus/HFM



Common Variable Immunodeficiency

- Most common symptomatic primary antibody ID in adults and children, ~ 1:10,000-50,000 Caucasian
- Onset after 4 years of age (usually in second decade)
- Decreased levels in 2 IgG, IgA, and/or IgM
- Absent isohemagglutinins, Poor response to vaccines
- Usually normal peripheral B cell numbers, classification based on B-cell subsets;
 - naïve B cells (IgM+IgD+CD27-);
 - IgM memory B cells (IgM+IgD+CD27+);
 - isotype-switched memory B cells (IgM-IgD-CD27+)
- Abnormal T cell number or function - common
- Several rare recessive genes found: routine genetic testing not recommended
 - ICOS, CD19, BAFF receptor, TNFRSF13B, TNFRSF13C, MSH5, TACI, APRIL

Common Variable Immunodeficiency

■ Presentation

- Predominantly recurrent bacterial infections of the respiratory and gastrointestinal tract
- Also viral, fungal and parasitic infections if T cell involved
- Autoimmune manifestations and malignancies
- AD-like eruptions (IgE elevated or normal), superimposed with viral/bacterial/fungal infections


Table 2. Summary of complications and incidence*

| | Numbers | Percentage |
|--------------------------|---------|------------|
| Infections | 428 | 90 |
| Autoimmunity | 97 | 25 |
| Lung impairment | 88 | 24 |
| Gastrointestinal disease | 51 | 14 |
| Malabsorption | 31 | 5 |
| Lymphoid malignancy | 36 | 10 |
| Previous splenectomy | 31 | 8 |
| Granulomatous disease | 31 | 8 |
| Other cancers | 21 | 6 |

*On the basis of on a cohort of 476 subjects. C Cunningham-Rundles, How I treat CVID, Blood Jul 10

Common Variable Immunodeficiency

- Treatment: Lifelong IVIG replacement
 - aim to reduce breakthrough infections rather than to achieve particular IgG trough level
- Infection outcomes in patients with CVID, JACI June 10




HyperIgE syndromes

- AD HIES - Coarse facies, severe eczema, and recurrent cold skin abscesses
- AR HIES (DOCK8 and TYK2) – bacteria cold skin abscess and severe viral infections



Figure 3. Classic atopic dermatitis-like skin lesion in an 18 year old Hyper-IgE-patient.





AD HyperIgE Syndrome




Table 1 | Summary of patient characteristics

| Patient ID | Age (yr) | Sex | stat3 mutation | HIES clinical score | Serum IgE* (IU ml ⁻¹) | Skeletal abnormalities | Recurrent candidiasis/staphylococcal abscess or lung infection | Atopic dermatitis |
|------------|----------|-----|----------------|---------------------|-----------------------------------|------------------------|--|-------------------|
| 1† (J112) | 6 | M | 1970 A→G (SH2) | 31 | 4,190 | + | + | + |
| 2 (J088) | 7 | M | 1145 G→T (DNA) | 70 | 18,000 | + | + | + |
| 3 (J083) | 10 | F | 1909 G→A (SH2) | 78 | 5,070 | + | + | + |
| 4 (J005) | 13 | F | 1144 C→T (DNA) | 60 | 18,600 | + | + | + |
| 5 (J100) | 22 | F | 1909 G→A (SH2) | 76 | 1,020 | + | + | + |
| 6 (J017) | 23 | M | 1145 G→A (DNA) | 82 | 20,500 | + | + | + |
| 7† (J002) | 24 | F | 1865 C→T (SH2) | 85 | 8,550 | + | + | + |
| 8† (J112) | 51 | M | 1970 A→G (SH2) | 79 | 6,380 | + | + | + |
| 9 (J054) | 40 | F | 1393 T→G (DNA) | 78 | 239 (47,338) | + | + | + |
| 10† (J002) | 56 | M | 1865 C→T (SH2) | 90 | 26 (2,392) | + | + | + |
| 11 | 48 | M | 1268 G→A (DNA) | 65 | 1,340 (20,700) | + | + | + |
| 12 | 37 | F | 1909 G→A | 94 | 495 (25,058) | + | + | + |
| 13 (J015) | 36 | F | 1861 T→G | 96 | | + | + | + |
| 14§ | 16 | M | None | 27 | 11,100 | – | – (other recurrent infections) | – |
| 15§ | 13 | F | None | 30 | 14,000 | – | – (other recurrent infections) | – |
| 16§ | 18 | F | None | n.a. | 136 | – | – (other recurrent infections) | – |
| 17 | 15 | M | None | 49 | 6,880 | + | – | + |
| 18 | 15 | M | None | 55 | 160 (69,280) | + | – | + |
| 19 | 4 | F | None | n.d. | >30,000 | + | – | + |


n.a., not available; n.d., not determined. *Peak values in parentheses. ††Parent-child pairs. §Siblings with similar phenotypes.

STAT 3 gene mutation with impaired TH17 cell differentiation discovered in subjects with AD HIES

Nature Apr 08

Panton-Valentine leukocidin (PVL)

- pore-forming toxin that targets polymorphonuclear leukocytes
- key role in the pathogenesis of necrotizing pneumonia



Polymorphonuclear leukocytes mediate *Staphylococcus aureus* Panton-Valentine leukocidin induced lung inflammation and injury, PNAS Mar 2010

Chronic Granulomatous Disease (CGD)

■ Infections

- Bacteria – Staph Aureus, Serratia
- Mycobacterium – BCGitis
- Fungus – Nocardia, Aspergillus

■ Granuloma



Recurrent perianal abscesses



BCGitis



Staph aureus bacteraemia, lymphadenitis and pneumatocoele



Nocardiosis

CGD clinical



- Hallmark of CGD is early onset of severe recurrent bacterial and fungal infections
 - Catalase positive organism: *Staph aureus*, *Burkholderia cepacia*, *Aspergillus* sp, *Nocardia* sp, and *Serratia marcescens*
- Most present during the first 5 years of life.
- Common presentations include the following infections:
 - Skin infections; Pneumonia/ Lung abscesses; Suppurative lymphadenitis; Diarrhea secondary to enteritis; Perianal or perirectal abscesses; Hepatic or splenic abscesses; Osteomyelitis, septicemia
- Second most common manifestation include development of granulomas in the skin, GI tract, and genitourinary tract

Chronic Granulomatous Disease






Figure 3. Relation among the Components of NADPH Oxidase That Are Affected in Patients with Chronic Granulomatous Disease. The membrane-bound phagocyte oxidase components, the 91-kd glycoprotein (gp91^{phox}) and the 22-kd protein (p22^{phox}), interact with the cytoplasmic components, the 47-kd protein (p47^{phox}) and the 67-kd protein (p67^{phox}). Glucose-6-phosphate dehydrogenase (G6PD) converts glucose-6-phosphate to 6-phosphogluconolactone, generating NADPH and a hydrogen ion from NADP⁺. NADPH oxidase catalyzes the monovalent reduction of O₂ to superoxide anion (O₂⁻), with the subsequent conversion to hydrogen peroxide (H₂O₂) by superoxide dismutase. Neutrophil-derived myeloperoxidase (MPO) converts hydrogen peroxide to hypochlorous acid (HOCl⁻ [bleach]), which is then converted to chlorine (Cl₂). The genes for the components of NADPH oxidase, their chromosomal locations, and the frequency of mutations as a cause of chronic granulomatous disease are indicated in the box.

Immunodeficiency diseases caused by defects in phagocytes, NEJM Dec 2000

CGD prone to Melioidosis



Hyper IgM Syndrome



- 70% X linked, Xq26, CD40 ligand glycoprotein
- Early sinopulmonary infections
 - Encapsulated bacteria, PCP, Cryptococcus, Parvovirus
- Intact IgM antibody response
- IgG and IgA < 2SD for age
- Absent antigen specific IgG
- Circulating B lymphocytes bear only IgD/IgM
- Cell mediated immunity may be impaired
- Subtype with recurrent/persistent neutropenia and thrombocytopenia

Hyper IgM syndromes





Figure 1. Schematic representation of the various known molecular defects leading to hyper IgM syndromes.

XHIGM has T cell defect and prone to *Pneumocystis jirovecii*



Response to an acute viral illness




Fig. 3.25.1 Response to an acute viral infection.

PIDs with Viral infections


- SCID

- Common respiratory virus -> ARDS

- STAT1 GOF

- Herpes virus eg. CMV, EBV


Primary Immunodeficiency due to Defects in Lymphocytes



Severe Combined Immunodeficiency



Lymphocyte Maturation and Development - SCID



SCID Clinical Presentation

- A Pediatric Emergency!!!
- Early presentation - Average age at diagnosis < 6mo
- Family history of early infant death from infections or recurrent infections
- Most frequent manifestations:
 - Oral candidiasis
 - Persistent diarrhea
 - Failure to thrive
 - Interstitial pneumonitis – viral/ PCP
 - Disseminated BCGitis


STAT1 GOF

| Type of infections | Patients (%) |
|--|-----------------|
| Mucocutaneous fungal infections | n = 274 |
| Oropharyngeal mycosis | 268 (98) |
| Cutaneous mycosis | 155 (57) |
| Esophageal/genital mycosis | 153 (56) |
| Onychomycosis | 153 (56) |
| Aphtous stomatitis | 125 (46) |
| Scalp mycosis | 55 (20) |
| Invasive fungal infections | 28 (10) |
| Invasive candidiasis | 10 (4) |
| Other invasive infections | 20 (7) |
| Bacterial infections* | 202 (74) |
| LRI | 129 (47) |
| ENT | 121 (44) |
| Skin | 77 (28) |
| Others† | 24 (9) |
| Mycobacterial infections | 17 (6) |
| Lung disease | 6 (2) |
| Adenitis/skin disease | 5 (2) |
| Disseminated disease | 6 (2) |
| Viral infections* | 103 (38) |
| Cutaneous | 88 (32) |
| Systemic | 23 (8) |

ENT: ear, nose, and throat.


*Probable or proven bacterial/viral infection.

†Severe acute gastroenteritis, septicemia, bone and joint infections, recurrent urinary tract infections.



Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype: an international survey of 274 patients from 167 kindreds, Blood Apr 2016

STAT1 GOF




Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes, Current opinion in immunology 2012


PIDs with chronic mucocutaneous candidiasis

| Disease | Molecular defect | Associated gene/transmission | Clinical picture |
|----------------------------|--|--|---|
| AD-HIES | Dominant-negative effect on multiple intracellular signaling pathways, including impaired generation of TH17 cells, and impaired intracellular signaling by receptors of IL-17 and 22. | STAT3, AD | Serious CMC, in particular fingernail, vaginal, and oral disease |
| APECED | Loss of tolerance, with persistence of autoreactive T cells, including the production of autoantibodies to cytokines (e.g., IL-17 and 22). | AIRE, AR | Serious CMC, usually arising within the first decade of life |
| SCID | Impaired generation of T cells, with or without accompanying B and NK lymphocytopenia. | IL2RG, X-linked; JAK3, AR; IL7R α , AR; CD3 δ , AR; CD3 ϵ , AR; RAG1, AR; RAG2, AR; ARTEMIS, AR; CD45, AR | CMC possible, perianal rash and thrush arise in the first few months of life |
| AR-HIES | Impaired T-cell activation, possibly impaired maintenance of memory Th17 cells or impaired formation of immunological synapse. | DOCK8, AR | Serious CMC |
| IL-12 and IL-23 deficiency | Impaired development of Th17 cells. | IL12B, AR; IL12RB1, AR | CMC but milder than in STAT3 deficiency |
| IL-17 deficiency | Impaired or abolished cellular responses to IL-17, due to either impaired production of or abolished response capacity to IL-17. | IL17F, AD; IL17RA, AR | Neonatal candidiasis, serious CMC |
| Dectin 1 deficiency [13] | Cell surface expression of the (mutated) receptor is lost, leading to impaired IL-6, IL-17 and TNF α on stimulation <i>in vitro</i> . | Dectin-1, AR | Increased susceptibility to vulvovaginal candidiasis and onychomycosis |
| CARD9 deficiency | Impaired function of signalosomes for dectin (dectin 1 and dectin 2) and other recognition molecules. | CARD9, AR | Severe or recurrent oral, vaginal candidiasis, dermatophytosis, invasive candidiasis (meningitis) |
| TYK2 deficiency | Adaptor molecule for several receptor complexes, including IL23 receptor. | TYK2, AR | Oral candidiasis |
| STAT1 mutations | The mutations in the coiled-coil domain of STAT1. | STAT1, AD | Severe CMC and dermatophytosis |


Chronic Mucocutaneous Candidiasis



Innate host defence and T cell responses to *Aspergillus fumigatus* infection



Clinical spectrum of Aspergillosis



ICH, immunocompromised host.

Aspergillus fumigatus morphology and dynamic host interactions, Nat Rev Microbiol 2017

Response to chronic/TB infection





Fig. 3.26.1 Mycobacteria elicit a Th1 response leading to granuloma formation.

Response to chronic/TB infection




PID with Mycobacterium infections

Table 1. Acquired and inherited conditions with mycobacterial susceptibility to BCG, NTM, or *Mycobacterium tuberculosis*

| | NTM | BCG | TB | TB only* | Other infections [†] | Physiopathology |
|---------------------------------|-----|-----|----|----------|-------------------------------|--|
| Acquired ID | | | | | | |
| Immunosuppressive treatment/BMT | + | ? | + | No | Yes | Impairment of immune cells |
| HIV | + | + | + | No | Yes | T-cell defect |
| Anti-IFN- γ antibodies | + | — | + | No | Yes | Impaired IFN- γ response |
| Anti-TNF- α antibodies | +/- | — | + | Yes | Yes | Impaired TNF- α response |
| Inherited ID | | | | | | |
| Cystic fibrosis | + | — | + | No | Yes | Alteration of the lungs |
| PID | | | | | | |
| SCID | — | + | + | No | Yes | T-cell defect |
| AD GATA2 deficiency | + | — | + | No | Yes | Quantitative defect of monocytes, DC, and PAP |
| CGD | +/- | + | + | No | Yes | Respiratory burst defect in all phagocytic cells |
| EDA-ID | + | + | + | No | Yes | Impaired CD40-dependent IL-12 production |
| XR CD40L deficiency | + | + | + | No | Yes | Impaired CD40-dependent IL-12 production |
| AR STAT1 deficiency | + | + | — | No | Yes | Impaired IFN- γ response |
| AR IRF8 deficiency | — | + | — | No | Yes | Absence of monocytes and DC |
| AR TYK2 deficiency | — | + | + | Yes | Yes | Impaired IFN- γ production |
| MSMD | | | | | | |
| IFN- γ R deficiencies | + | + | + | Yes | No | Impaired IFN- γ response |
| AD STAT1 deficiency | + | + | + | Yes | No | Impaired IFN- γ response |
| XR gp91phox deficiency | — | + | + | Yes | No | Respiratory burst defect in macrophages |
| AD IRF8 deficiency | — | + | — | No | No | Absence of CD11C ⁺ CD1c ⁺ DC |
| XR NEMO deficiency | + | + | + | No | No | Impaired CD40-dependent IL-12 production |
| IL-12 and IL-12R deficiencies | + | + | + | Yes | Yes | Impaired IFN- γ production |
| AR ISG15 deficiency | — | + | — | No | No | Impaired IFN- γ production |

PID with Mycobacterium infections



4 Stages of Immunologic Testing when Primary Immunodeficiency is Suspected

1

- History and physical examination, height and weight
- CBC and differential
- Quantitative Immunoglobulin levels IgG, IgM, IgA (related to age)

✓

2

- Specific antibody responses (tetanus, diphtheria)
- Response to pneumococcal vaccine (pre/post) (for ages 3 and up)
- IgG subclass analysis

X

3

- Candida and Tetanus skin tests
- Lymphocyte surface markers CD3/CD4/CD8/CD19/CD16/CD56
- Mononuclear lymphocyte proliferation studies (using mitogen and antigen stimulation)
- Neutrophil oxidation burst (if indicated)

✓

4

- Complement screening CH50, C3, C4
- Enzyme measurements (adenosine deaminase, purine nucleoside phosphorylase)
- Phagocyte studies (surface glycoproteins, mobility, phagocytosis)
- NK cytotoxicity studies
- Further complement studies AH50
- Neo antigen to test antibody production
- Other surface/cytoplasmic molecules
- Cytokine receptor studies
- Family/genetic studies


✓

X

Recurrent LRTI


- Impaired respiratory barrier like cystic fibrosis, primary ciliary dyskinesia, CCAM
- Aspiration pneumonia/ GER/ swallowing dysfunction
- Asthma
- Protracted bacteria bronchitis
- PID
 - Antibody defect, Phagocytic defect, HIES, CID, complement deficiency
- Immunology Tests:
 1. FBC, Ig G,A,M,E, C3,C4,CH50
 2. Vaccine antibodies
 3. T/NK lymphocyte subsets if viral/fungal/TB

The Microbiome in Asthma




The microbiome in asthma: Role in pathogenesis, phenotype, and response to treatment,
Ann Allergy Asthma Immunol 2019 Mar


Immunology of Asthma



Treatment for Asthma




Immunotherapy for Asthma



Treatment for Asthma - Biologics

Targets for current and pipeline biologics

The discovery that asthma is a heterogeneous disease has paved the way for new, targeted biologic therapies. Omalizumab, which targets immunoglobulin E (IgE), was the first to be approved over a decade ago and at least six biologics that target interleukins have now reached human trials.



Summary

■ PID respiratory infections

- Bacteria
 - XLA - Streptococcal, Pseudomonas
 - CGD - Staph Aureus, Meiloidosis
 - AD HIES - Staph Aureus lung abscess
- Viral
 - SCID - viral URTI/ARDS
 - STAT1 GOF – CMV pneumonitis
- Fungal
 - SCID/XHIGM – PCP
 - STAT1 GOF – Candida, Aspergillus
 - CGD – Aspergillus, Nocardia
 - HIES - Candida
- Mycobacterium
 - SCID, CGD, MSMD

Suspect PID if:

- Pneumonia ≥ 2 per year
- Sinus infection ≥ 2 per year
- Ear infections ≥ 4 per year
- Bronchiectasis
- ARDS from common respiratory infections

Questions?

Dr Liew Woei Kang

MBBS, MRCPCH (UK), FAMS (Paediatrics), FAAAAI (USA)

Consultant Paediatrician

Paediatric Immunology & Allergy



Allergy

Food allergy – diagnostic tests (SPT and Bld IgE), food challenge, oral immunotherapy

Respiratory allergy – Asthma and AR Tm, SPT, lung function testing, allergen immunotherapy

Skin allergy – Eczema and Urticaria, SPT, skin patch testing

Drug and vaccine allergy – diagnostic tests, drug challenge, drug desensitisation

Immunology

Evaluation of primary immunodeficiency/recurrent infections/periodic fever syndromes

Genetic testing of index case and family

IVIG replacement, SC interferon gamma

Haematopoietic stem cell transplant for PID

Rheumatology

Evaluation of inflammatory disorders/ joint pains and autoimmunity

Juvenile idiopathic arthritis – diagnostics, intraarticular injection, biologics

Vasculitis – Kawasaki, Henoch Schlein Purpura